DK2691110T3 - Midler og fremgangsmåder til aktiv cellulær immunterapi af cancer ved anvendelse af tumorceller, der er dræbt ved højt hydrostatisk tryk, og dendritiske celler - Google Patents
Midler og fremgangsmåder til aktiv cellulær immunterapi af cancer ved anvendelse af tumorceller, der er dræbt ved højt hydrostatisk tryk, og dendritiske celler Download PDFInfo
- Publication number
- DK2691110T3 DK2691110T3 DK12734884.5T DK12734884T DK2691110T3 DK 2691110 T3 DK2691110 T3 DK 2691110T3 DK 12734884 T DK12734884 T DK 12734884T DK 2691110 T3 DK2691110 T3 DK 2691110T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- tumor
- tumor cells
- pharmaceutical composition
- dendritic cells
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title claims description 176
- 210000004443 dendritic cell Anatomy 0.000 title claims description 149
- 206010028980 Neoplasm Diseases 0.000 title claims description 91
- 238000009931 pascalization Methods 0.000 title claims description 73
- 238000000034 method Methods 0.000 title claims description 22
- 201000011510 cancer Diseases 0.000 title claims description 21
- 238000009169 immunotherapy Methods 0.000 title description 10
- 230000001413 cellular effect Effects 0.000 title description 6
- 210000004027 cell Anatomy 0.000 claims description 84
- 238000011282 treatment Methods 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 206010060862 Prostate cancer Diseases 0.000 claims description 33
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 33
- 230000001640 apoptogenic effect Effects 0.000 claims description 24
- 238000002255 vaccination Methods 0.000 claims description 22
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 230000002706 hydrostatic effect Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000001338 necrotic effect Effects 0.000 claims description 3
- 230000032832 immune response to tumor cell Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 31
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 27
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 27
- 230000004083 survival effect Effects 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 210000003289 regulatory T cell Anatomy 0.000 description 17
- 230000006698 induction Effects 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 230000035800 maturation Effects 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 230000002163 immunogen Effects 0.000 description 13
- 102100037907 High mobility group protein B1 Human genes 0.000 description 12
- 238000002619 cancer immunotherapy Methods 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 230000037449 immunogenic cell death Effects 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 102000004082 Calreticulin Human genes 0.000 description 11
- 108090000549 Calreticulin Proteins 0.000 description 11
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 11
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 230000028993 immune response Effects 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 206010057249 Phagocytosis Diseases 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 230000008782 phagocytosis Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 5
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 5
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 5
- 101150031823 HSP70 gene Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940045799 anthracyclines and related substance Drugs 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 101150052825 dnaK gene Proteins 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000009566 cancer vaccine Methods 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000037455 tumor specific immune response Effects 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011472 radical prostatectomy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 description 2
- 101710168586 Advanced glycosylation end product-specific receptor Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011342 chemoimmunotherapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011293 immunotherapeutic strategy Methods 0.000 description 2
- 231100000619 immunotoxicology Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241001326189 Gyrodactylus prostae Species 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Farmaceutisk sammensætning til inducering af en immunreaktion mod tumorceller, omfattende a) tumorceller, der er apoptotiske, forårsaget af behandling med højt hydrostatisk tryk lig med eller større end 100 MPa i 10 minutter til 2 timer og b) dendritiske celler.
2. Farmaceutisk sammensætning ifølge krav 1, kendetegnet ved, at tumorcellerne blev behandlet med hydrostatisk tryk i mindst 10 minutter ved et tryk på mindst 200 MPa.
3. Farmaceutisk sammensætning ifølge krav 1, kendetegnet ved, at tumorcellerne blev behandlet med hydrostatisk tryk på 200-300 MPa.
4. Farmaceutisk sammensætning ifølge et af kravene 1-3, kendetegnet ved, at de apoptotiske tumorceller ikke er nekrotiske.
5. Farmaceutisk sammensætning ifølge et af de foregående krav, kendetegnet ved, at tumorcellerne blev afledt fra tumorcellelinjer.
6. Farmaceutisk sammensætning ifølge et af kravene 1-4, kendetegnet ved, at tumorcellerne blev afledt fra en tumor, der blev isoleret fra den patient, der skal behandles.
7. Farmaceutisk sammensætning ifølge et af kravene 1-6, kendetegnet ved, at umodne dendritiske celler blev ladet med apoptotiske tumorceller, der er blevet behandlet med højt hydrostatisk tryk.
8. Farmaceutisk sammensætning ifølge krav 7, kendetegnet ved, at de umodne dendritiske celler blev opnået ved leukaferese.
9. Farmaceutisk sammensætning ifølge krav 8, kendetegnet ved, at de umodne dendritiske celler blev opnået ved leukaferese og dyrkning in vitro i nærvær af cytokiner.
10. Farmaceutisk sammensætning ifølge et af kravene 1 til 9 til anvendelse hos patienter, der lider af cancer både på et tidligt stadie og på et sent stadie.
11. Farmaceutisk sammensætning ifølge et af kravene 1 til 9 til anvendelse ved behandling af cancer, omfattende prostatacancer, æggestokkræft eller akut lymfoblastisk leukæmi.
12. Fremgangsmåde til fremstilling afen farmaceutisk sammensætning ifølge et af kravene 1-9, kendetegnet ved, at umodne dendritiske celler lades med apoptotiske tumorceller, der er blevet behandlet med højt hydrostatisk tryk lig med eller større end 100 MPa, og efterfølgende modning af de dendritiske celler.
13. Fremgangsmåde til fremstilling afen farmaceutisk sammensætning ifølge krav 12 til anvendelse til cancervaccinering af mennesker, omfattende ladning af umodne dendritiske celler med tumorceller, hvor tumorcellerne omdannes til et apoptotisk stadie ved behandling med højt hydrostatisk tryk lig med eller større end 100 MPa i 10 minutter til 2 timer, hvorved de dendritiske celler eventuelt modnes, før den farmaceutiske sammensætning anvendes.
14. Fremgangsmåde til fremstilling afen farmaceutisk sammensætning ifølge krav 12 til anvendelse til cancervaccinering af mennesker, omfattende ladning af umodne dendritiske celler med tumorceller, der er opnået fra en tu-morcellelinje, og som omdannes til et apoptotisk stadie ved behandling med højt hydrostatisk tryk lig med eller større end 100 MPa i 10 minutter til 2 timer, hvorved de dendritiske celler eventuelt modnes, før den farmaceutiske sammensætning anvendes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504387P | 2011-07-05 | 2011-07-05 | |
| EP11172622A EP2543386A1 (en) | 2011-07-05 | 2011-07-05 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure |
| PCT/EP2012/062950 WO2013004708A1 (en) | 2011-07-05 | 2012-07-04 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2691110T3 true DK2691110T3 (da) | 2014-11-17 |
Family
ID=44359435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12734884.5T DK2691110T3 (da) | 2011-07-05 | 2012-07-04 | Midler og fremgangsmåder til aktiv cellulær immunterapi af cancer ved anvendelse af tumorceller, der er dræbt ved højt hydrostatisk tryk, og dendritiske celler |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20140086957A1 (da) |
| EP (2) | EP2543386A1 (da) |
| JP (1) | JP5986196B2 (da) |
| KR (1) | KR102035873B1 (da) |
| CN (3) | CN109125347A (da) |
| AU (2) | AU2012280322B2 (da) |
| BR (2) | BR122019026627B1 (da) |
| CA (1) | CA2833946A1 (da) |
| DK (1) | DK2691110T3 (da) |
| EA (1) | EA030061B1 (da) |
| ES (1) | ES2525759T3 (da) |
| PL (1) | PL2691110T3 (da) |
| PT (1) | PT2691110E (da) |
| RS (1) | RS53713B1 (da) |
| RU (1) | RU2012127685A (da) |
| SG (1) | SG194201A1 (da) |
| SI (1) | SI2691110T1 (da) |
| SM (1) | SMT201400188B (da) |
| UA (1) | UA111738C2 (da) |
| WO (1) | WO2013004708A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130011438A1 (en) | 2011-07-05 | 2013-01-10 | SOTIO a.s. | Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells |
| US9562219B2 (en) | 2013-12-27 | 2017-02-07 | SOTIO a.s. | Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer |
| CN104258384B (zh) * | 2014-09-29 | 2017-05-03 | 北京时合生物科技有限公司 | 一种基于树突状细胞的特异性肿瘤疫苗的制备方法 |
| CA2991212A1 (en) * | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
| CN106244543A (zh) * | 2016-07-29 | 2016-12-21 | 北京时合生物科技有限公司 | 一种pbmc体外诱导分化成为树突状细胞的方法 |
| JP2020507616A (ja) * | 2017-02-17 | 2020-03-12 | アイビタ バイオメディカル インコーポレイテッド | 改変された腫瘍細胞および改変された樹状細胞を使用して、腫瘍免疫原性を増強する方法および自己癌免疫療法製品の組成物 |
| WO2019101110A1 (zh) * | 2017-11-21 | 2019-05-31 | 中国科学院上海药物研究所 | 天花粉蛋白用于致敏和/激活树突状细胞中的应用 |
| KR20200116112A (ko) * | 2018-01-25 | 2020-10-08 | 소티오 에이.에스. | 화학요법에 순차적인 수지상 세포 백신접종 |
| US20210060146A1 (en) | 2018-01-25 | 2021-03-04 | SOTIO a.s. | Dendritic cell vaccination in parallel to chemotherapy |
| WO2020187975A1 (en) | 2019-03-19 | 2020-09-24 | SOTIO a.s. | Patient selection for treatment with dendritic cell vaccination |
| JP7340240B2 (ja) * | 2019-08-26 | 2023-09-07 | 学校法人関西医科大学 | 細胞又は組織にアポトーシスを誘導する方法 |
| WO2022171792A1 (en) | 2021-02-12 | 2022-08-18 | Sctbio A.S. | Patient selection for treatment with dendritic cell vaccination |
| CA3225815A1 (en) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN114807229A (zh) * | 2022-05-27 | 2022-07-29 | 中国科学院长春应用化学研究所 | 细胞膜、纳米疫苗及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042564A2 (en) * | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
| EP1814981A4 (en) | 2004-10-25 | 2009-09-30 | Baylor Res Inst | HEAT-SHOCK-TREATED MELANOMA CELLS LOAD DENDRITICAL CELLS |
| US8420078B2 (en) * | 2005-03-10 | 2013-04-16 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
| KR100647847B1 (ko) * | 2005-05-27 | 2006-11-23 | 크레아젠 주식회사 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 |
-
2011
- 2011-07-05 EP EP11172622A patent/EP2543386A1/en not_active Withdrawn
-
2012
- 2012-04-07 UA UAA201312611A patent/UA111738C2/uk unknown
- 2012-07-03 RU RU2012127685/15A patent/RU2012127685A/ru unknown
- 2012-07-04 KR KR1020137032259A patent/KR102035873B1/ko active IP Right Grant
- 2012-07-04 PT PT127348845T patent/PT2691110E/pt unknown
- 2012-07-04 AU AU2012280322A patent/AU2012280322B2/en active Active
- 2012-07-04 RS RS20140685A patent/RS53713B1/en unknown
- 2012-07-04 BR BR122019026627-1A patent/BR122019026627B1/pt active IP Right Grant
- 2012-07-04 CN CN201810985605.9A patent/CN109125347A/zh active Pending
- 2012-07-04 DK DK12734884.5T patent/DK2691110T3/da active
- 2012-07-04 CN CN201280032974.7A patent/CN103648524B/zh active Active
- 2012-07-04 EA EA201301089A patent/EA030061B1/ru unknown
- 2012-07-04 ES ES12734884.5T patent/ES2525759T3/es active Active
- 2012-07-04 SG SG2013077128A patent/SG194201A1/en unknown
- 2012-07-04 US US14/113,337 patent/US20140086957A1/en not_active Abandoned
- 2012-07-04 BR BR112013031084-7A patent/BR112013031084B1/pt active IP Right Grant
- 2012-07-04 CN CN2012102924999A patent/CN102861103A/zh active Pending
- 2012-07-04 EP EP12734884.5A patent/EP2691110B1/en active Active
- 2012-07-04 JP JP2014517778A patent/JP5986196B2/ja active Active
- 2012-07-04 CA CA2833946A patent/CA2833946A1/en active Pending
- 2012-07-04 WO PCT/EP2012/062950 patent/WO2013004708A1/en active Application Filing
- 2012-07-04 PL PL12734884T patent/PL2691110T3/pl unknown
- 2012-07-04 SI SI201230120T patent/SI2691110T1/sl unknown
-
2014
- 2014-12-17 SM SM201400188T patent/SMT201400188B/xx unknown
-
2016
- 2016-09-28 AU AU2016234915A patent/AU2016234915B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2691110A1 (en) | 2014-02-05 |
| BR112013031084A2 (pt) | 2016-11-29 |
| KR102035873B1 (ko) | 2019-10-23 |
| BR122019026627B1 (pt) | 2021-01-12 |
| ES2525759T3 (es) | 2014-12-30 |
| SMT201400188B (it) | 2015-03-05 |
| JP5986196B2 (ja) | 2016-09-06 |
| AU2016234915B2 (en) | 2017-08-31 |
| SI2691110T1 (sl) | 2015-01-30 |
| EP2543386A1 (en) | 2013-01-09 |
| PL2691110T3 (pl) | 2015-03-31 |
| JP2014520780A (ja) | 2014-08-25 |
| WO2013004708A1 (en) | 2013-01-10 |
| CN103648524B (zh) | 2016-08-17 |
| EP2691110B1 (en) | 2014-10-29 |
| EA201301089A1 (ru) | 2014-05-30 |
| US20140086957A1 (en) | 2014-03-27 |
| RS53713B1 (en) | 2015-04-30 |
| SG194201A1 (en) | 2013-11-29 |
| CA2833946A1 (en) | 2013-01-10 |
| PT2691110E (pt) | 2014-12-22 |
| BR112013031084B1 (pt) | 2021-01-12 |
| AU2012280322B2 (en) | 2016-07-21 |
| EA030061B1 (ru) | 2018-06-29 |
| RU2012127685A (ru) | 2014-01-20 |
| UA111738C2 (uk) | 2016-06-10 |
| CN109125347A (zh) | 2019-01-04 |
| AU2016234915A1 (en) | 2016-10-20 |
| KR20140040734A (ko) | 2014-04-03 |
| NZ618000A (en) | 2014-12-24 |
| CN102861103A (zh) | 2013-01-09 |
| CN103648524A (zh) | 2014-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016234915B2 (en) | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells | |
| AU2012280322A1 (en) | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells | |
| US10918704B2 (en) | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells | |
| JP6235085B2 (ja) | 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法 | |
| JP6134763B2 (ja) | ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
| EP1912672B1 (en) | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response | |
| US20130129713A1 (en) | Method of antigen loading for immunotherapy | |
| Lemoine et al. | Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer | |
| Su et al. | Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models | |
| Weiss et al. | Selected anti-tumor vaccines merit a place in multimodal tumor therapies | |
| JP2006518219A (ja) | 電気穿孔法による細胞への抗原の負荷方法 | |
| Shan et al. | Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response | |
| Radej et al. | Immunomodelling characteristics of mature dendritic cells stimulated by colon cancer cells lysates | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
| NZ618000B2 (en) | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells | |
| Khamisabadi et al. | Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice | |
| Faries et al. | Intralesional Bacille Calmette-Guerin in melanoma: a forgotten modality of in situ immunization |